Fulvia Troise

Nouscom (Italy) — Italy

Immunology and Microbiology · Life Sciences

14h-index845citations57works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(33), Monoclonal and Polyclonal Antibodies Research(33), vaccines and immunoinformatics approaches(26), Cancer Immunotherapy and Biomarkers(8), CAR-T cell therapy research(8)

Publications57 total

Neoadjuvant personalized viral vaccine prevents tumor relapse in checkpoint-resistant murine melanoma model
Journal for ImmunoTherapy of Cancer·2025Open Access
Abstract B053: Neoadjuvant Personalized Viral Vectored vaccines are highly effective against tumor relapse in checkpoint inhibitor resistant murine models
Cancer Immunology Research·2024· 1 cited
Supplementary Table 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
Data from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
Supplementary Figure 3 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
Supplementary Figure 3 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
Supplementary Figure 5 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
Data from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
Supplementary Figure 6 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
Supplementary Table 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
Supplementary Figure 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
Supplementary Figure 6 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
Supplementary Figure 4 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
Supplementary Figure 5 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
Supplementary Figure 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
Supplementary Figure 2 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
Supplementary Figure 4 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
Supplementary Figure 2 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024Open Access
Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine
Vaccines·2024· 1 citedOpen Access
Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Cancer Immunology Research·2024· 10 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Elisa Scarselli(32), Anna Morena D’Alise(31), Guido Leoni(31), Gabriella Cotugno(30), Irene Garzia(27), Linda Nocchi(19), Giuseppina Colonna Romano(19), Simona Allocca(18), Laura Seclì(17), Lidia Avalle(16), Alfredo Nicosia(16), Valeria Poli(15), Laura Antonucci(15), Laura Conti(13), Carmen Caiazza(13), Massimo Mallardo(13), Armin Lahm(12), Francesca Langone(11), Veronica Bignone(11), Fabio Giovanni Tucci(11)